Compliance With Once Daily Glaucoma Medication
Completed
- Conditions
- Compliance
- Registration Number
- NCT00333463
- Lead Sponsor
- Alcon Research
- Brief Summary
A study to examine patient compliance with once daily glaucoma medication
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
- Primary open angle glaucoma or ocular hypertension patients
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms influence adherence to once-daily glaucoma medications like prostaglandin analogs?
How does once-daily dosing compare to multiple-dose regimens in managing intraocular pressure for glaucoma patients?
Are there specific biomarkers that correlate with improved compliance in chronic glaucoma treatment protocols?
What adverse events are associated with long-term use of once-daily beta-blockers or alpha agonists for glaucoma?
What combination therapies enhance adherence in glaucoma management compared to monotherapy approaches?
Trial Locations
- Locations (1)
Ft. Worth
🇺🇸Ft. Worth, Texas, United States
Ft. Worth🇺🇸Ft. Worth, Texas, United States